Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2011

View Archived Issues

Spotlight on myotonic dystrophy: Misregulated alternative BIN1 splicing linked to muscle weakness

Novel antineoplastic agents presented

Topline phase III data on HyQ in primary immunodeficiency

NVP-BEZ-235/everolimus combination displays synergistic antitumor effects in models of NSCLC

CUPID trial supports safety and efficacy of Mydicar intracoronary gene therapy for heart failure

Niclosamide inhibits protein involved in colon cancer metastasis

Rectogesic slows lymphatic transit time of snake venom

Boehringer Ingelheim patents novel chemokine CCR2 receptor antagonists

New nicotinic acetylcholine alpha7 receptor ligands presented by NeuroSearch

Novel metabotropic mGlu5 glutamate receptor modulators developed

Novartis synthesizes new orexin receptor antagonists

French universities patent new agents for herpes simplex virus infection

Evotec and UCB form drug discovery collaboration for CNS disorders

NovaBay Pharmaceuticals provides pipeline update

Sinapis Pharma completes phase I trial of methamphetamine hydrochloride

Mesoblast receives FDA clearance for phase III bone marrow regeneration trial

Novartis initiates phase II LCQ-908 trial in hepatitis C

Achillion begins phase I trial of ACH-2928 for treatment of hepatitis C

Resminostat receives FDA orphan status in hepatocellular cancer

Eisai Europe reports phase III results showing efficacy of zonisamide in newly diagnosed epilepsy

Ildong Pharmaceutical to sell pirfenidone in South Korea under license agreement with Shionogi

Genfit reports encouraging phase II data on GFT-505 in diabetes

Treatment begins in phase Ib Ampion trial in osteoarthritis of the knee

Ipsen and Institut de cancerologie Gustave Roussy sign 3-year oncology partnership

PharmaVentures to assist Avexa in out-licensing apricitabine for HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...